Kyongbo Pharmaceutical Co Ltd (KO:214390) — Market Cap & Net Worth
Market Cap & Net Worth: Kyongbo Pharmaceutical Co Ltd (214390)
Kyongbo Pharmaceutical Co Ltd (KO:214390) has a market capitalization of $87.65 Million (₩129.34 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19768 globally and #1017 in its home market, demonstrating a 0.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kyongbo Pharmaceutical Co Ltd's stock price ₩5410.00 by its total outstanding shares 23906860 (23.91 Million). Also see 214390 total asset value for a full breakdown of the balance sheet.
Kyongbo Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Kyongbo Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $210.25 Million to $87.65 Million (-7.55% CAGR). Also see Kyongbo Pharmaceutical Co Ltd (214390) cash flow conversion for how efficiently the company converts equity into cash flow.
Kyongbo Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kyongbo Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 214390 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.51x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $209.59 Million | $186.73 Billion | $12.71 Billion | 0.00x | 0.02x |
| 2017 | $192.39 Million | $191.66 Billion | $17.96 Billion | 0.00x | 0.01x |
| 2018 | $160.34 Million | $201.34 Billion | $13.12 Billion | 0.00x | 0.01x |
| 2019 | $130.81 Million | $191.71 Billion | $5.29 Billion | 0.00x | 0.02x |
| 2020 | $260.59 Million | $215.29 Billion | $9.40 Billion | 0.00x | 0.03x |
| 2021 | $172.14 Million | $170.66 Billion | -$7.50 Billion | 0.00x | N/A |
| 2022 | $161.05 Million | $196.26 Billion | $610.59 Million | 0.00x | 0.26x |
| 2023 | $135.93 Million | $216.36 Billion | $2.97 Billion | 0.00x | 0.05x |
| 2024 | $100.77 Million | $238.56 Billion | $4.64 Billion | 0.00x | 0.02x |
| 2025 | $93.48 Million | $264.10 Billion | $182.29 Million | 0.00x | 0.51x |
Competitor Companies of 214390 by Market Capitalization
Companies near Kyongbo Pharmaceutical Co Ltd in the global market cap rankings as of September 18, 2026. Review Kyongbo Pharmaceutical Co Ltd (214390) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kyongbo Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Kyongbo Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kyongbo Pharmaceutical Co Ltd's market cap moved from $210.25 Million to $ 87.65 Million, with a yearly change of -7.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩87.65 Million | -6.24% |
| 2025 | ₩93.48 Million | -7.23% |
| 2024 | ₩100.77 Million | -25.86% |
| 2023 | ₩135.93 Million | -15.60% |
| 2022 | ₩161.05 Million | -6.45% |
| 2021 | ₩172.14 Million | -33.94% |
| 2020 | ₩260.59 Million | +99.21% |
| 2019 | ₩130.81 Million | -18.42% |
| 2018 | ₩160.34 Million | -16.66% |
| 2017 | ₩192.39 Million | -8.21% |
| 2016 | ₩209.59 Million | -0.31% |
| 2015 | ₩210.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Kyongbo Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.65 Million USD |
| MoneyControl | $87.65 Million USD |
| MarketWatch | $87.65 Million USD |
| marketcap.company | $87.65 Million USD |
| Reuters | $87.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more